The clinical characteristics and prognostic factors of multiple lesions in glioblastomas
暂无分享,去创建一个
[1] S. Sangkhathat,et al. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching , 2020, Clinical Neurology and Neurosurgery.
[2] Dong Kyu Lee,et al. Survival analysis: part II – applied clinical data analysis , 2019, Korean journal of anesthesiology.
[3] J. Debus,et al. Survival and recurrence patterns of multifocal glioblastoma after radiation therapy , 2018, Cancer management and research.
[4] Sanguansin Ratanalert,et al. Butterfly Tumor of the Corpus Callosum: Clinical Characteristics, Diagnosis, and Survival Analysis , 2017, Journal of Neurosciences in Rural Practice.
[5] F. Gaillard,et al. Multifocal and multicentric glioblastoma: Improved characterisation with FLAIR imaging and prognostic implications , 2016, Journal of Clinical Neuroscience.
[6] F. Gaillard,et al. The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma , 2016, Journal of Neuro-Oncology.
[7] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[8] Jayesh Sardhara,et al. Multiple glioblastomas: Are they different from their solitary counterparts? , 2015, Asian journal of neurosurgery.
[9] Yuexin Liu,et al. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma , 2015, Acta Neuropathologica.
[10] J. Hay,et al. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. , 2013, Neuro-oncology.
[11] R. Lober,et al. The incidence and significance of multiple lesions in glioblastoma , 2013, Journal of Neuro-Oncology.
[12] Mitchel S Berger,et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. , 2012, Journal of neurosurgery.
[13] K. Black,et al. Prognosis of patients with multifocal glioblastoma: a case-control study. , 2012, Journal of neurosurgery.
[14] S. Inoue,et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. , 2012, Genes & development.
[15] Bin Wu,et al. Subgroup Economic Analysis for Glioblastoma in a Health Resource-Limited Setting , 2012, PloS one.
[16] Nicholas B. Levine,et al. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. , 2011, Journal of neurosurgery.
[17] R. Stupp,et al. Cost–effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme , 2009, Expert review of pharmacoeconomics & outcomes research.
[18] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[19] Sooriyarachchi,et al. Use of Schoenfeld’s global test to test the proportional hazards assumption in the Cox proportional hazards model: an application to a clinical study , 2009 .
[20] Maiwenn J Al,et al. Cost‐effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme , 2008, Cancer.
[21] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[22] R. Mirimanoff,et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost‐identification analysis of concomitant and adjuvant treatment with temozolomide until patient death , 2004, Cancer.
[23] C. Mann,et al. Observational research methods. Research design II: cohort, cross sectional, and case-control studies , 2003, Emergency medicine journal : EMJ.
[24] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[25] H. Abe,et al. Clinicopathological study of multiple gliomas--report of three cases. , 1990, Neurologia medico-chirurgica.
[26] D. Karnofsky,et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .